Brain scans reveal why dieting fails?
NCT ID NCT03578887
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study used MRI brain scans in twins to investigate whether brain inflammation (gliosis) plays a role in obesity and weight regain. Researchers compared people undergoing behavioral weight loss, bariatric surgery, and healthy-weight controls. The goal was to understand why weight loss is often temporary and whether surgery resets the brain's weight set point.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal why weight regain is common after dieting and point to new brain-focused treatments for obesity.
- What could go wrong
- This is an observational study, not a treatment trial. Results may not lead to direct therapies, and findings may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
112 people
The number who actually took part.
- Started
-
Jun 2019
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 25-64 years * Behavioral Weight Loss (BWL) \& Surgical Weight Loss (SWL) (Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy): BMI 30- \<56 kg/m² * RYGB and Sleeve Gastrectomy: eligible for RYGB or Sleeve Gastrectomy and not undergoing revision or reoperation * Healthy Weight Controls (HWC): BMI 18.5-24.9 kg/m² Exclusion Criteria: * Poorly controlled hypertension or coronary artery disease, or chronic disease (e.g. cancer, multiple sclerosis, autoimmune disease, rheumatic disease) Blood Pressure \> 160/100 mmHG Heart Rate \> 110 bpm * Chronic kidney disease (GFR \<60 mL/min/1.73 m2), * Presence of cirrhosis (Nonalcoholic Fatty Liver Disease (NALFD)/Nonalcoholic Steatohepatitis (NASH) are acceptable), * Previous or planned (during the study period) obesity treatment with surgery (planned surgery ok for the SWL group) or a weight loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed \> 1 year before screening, (2) lap banding, if the band has been removed \> 1 year before screening, (3) intragastric balloon, if the balloon has been removed \> 1 year before screening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \> 1 year before screening, * A1c \> 8.5% in Bariatric group; A1c ≥ 6.5% for BWL and HWC groups, * Current use of insulin (insulin ok for Surgical Weight Loss group, also called SWL), DPP-4 inhibitors, thiazolidinediones or medications known to alter metabolic function (e.g. atypical antipsychotics, corticosteroids), * Pregnancy or breastfeeding, * MRI contraindications (e.g. implanted metal, claustrophobia), or unable to have MRI or fit in MRI scanner * Current smoking/daily use of nicotine containing products (cigarettes, e-cigarettes, vaping or other nicotine containing products) or heavy alcohol use, * Weight \>450 pounds (iDXA limit), * Weight-reduced from lifetime maximum weight by \>16%, * Weight not stable over past 3 months (±10%), * T2D (for BWL or HWC), * Inability to participate in a weight loss program (BWL) * History of eating disorder or current eating disorder, currently enrolled in a weight loss program (ok for the SWL group provided weight stability and lifetime weight-reduced maximum conditions are met) or taking medications to lose weight * Severe food allergies * Any condition that the study physician determines to be unsafe for participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Washington - South Lake Union
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which exercise dose best helps kids with metabolic syndrome?
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can electrical muscle stimulation boost exercise benefits after menopause?